Authors
Chongyu Zhang, Qiankun Wang, Mengchen Zhu, Xiaowen Li, Ji Li, Xi Liu, Qinggong Yuan, Yan Zhang, Wunai Zhang, Junhui Li, Wenbin Yang, Nanbin Liu
Published in
Molecular and cellular probes. Pages 102082. Aug 06, 2026. Epub Aug 06, 2026.
Abstract
The DExD/H-box (DDX) helicase family plays critical roles in RNA metabolism and has been implicated in tumorigenesis. However, the pan-cancer activities and prognostic potential of DDX52, especially in liver hepatocellular carcinoma (LIHC), are largely unknown.
We comprehensively analyzed DDX52 across pan-cancer using TCGA, GEO, HPA, and SpatialTME databases, assessing its differential expression, prognosis, genetic alterations, Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and immune microenvironment features. In LIHC, we performed functional enrichment, PPI network, single-cell sequencing, and drug sensitivity analyses. Molecular docking explore potential small-molecule inhibitors of DDX52. Finally, we validated DDX52 expression and function in LIHC.
DDX52 mRNA and protein expression were significantly upregulated in multiple malignancies, including LIHC. Elevated DDX52 expression correlated with poor prognosis in LIHC. Genetic analysis revealed frequent copy number variations (CNV) and single-nucleotide variants (SNV) of DDX52, with significant positive correlations between DDX52 expression and both TMB and MSI across numerous cancer types. DDX52 expression was also significantly associated with immune cell infiltration, immune checkpoint molecules. In LIHC, DDX52 was predominantly expressed in B cells, proliferating T cells, malignant cells, and monocytes/macrophages. Functional enrichment analysis indicated DDX52 involvement in metabolic processes, histone modification, cell cycle regulation, and oncogenic signaling pathways. Pharmacologically, high DDX52 expression correlated with reduced drug sensitivity. Experimentally, DDX52 silencing significantly inhibited proliferation, colony formation, migration, and invasion in HepG2 and MHCC-97H cells.
Our integrative analyses and experimental validation suggest that DDX52 is a potential prognostic biomarker and therapeutic target in LIHC. Its associations with immune features and multiple cancer-related pathways provide hypotheses for future mechanistic investigation.
PMID:
42562310
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0